Small Molecules that Modify RNA Expression

Founded by Bill Haney and Kathleen McCarthy, Skyhawk is at the leading edge of Boston’s bio-pharma revolution. Skyhawk’s novel approach corrects the underlying genetics of disease at the RNA level. Their drugs can modify expression of target genes previously considered undruggable for a variety of diseases such as cancer, neurogenerative, autoimmune, inflammatory, and infectious diseases. Take a look at the bio-pharma marketing work we produced including evolving their brand and creating a website that communicates their current a future successes.